The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
(1989) · PubMed · Cited by 1,639
The Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,463
DNA Origami with Complex Curvatures in Three-Dimensional Space
Han, D., Pal, S., Nangreave, J., Deng, Z., Liu, Y., & Yan, H. (2011) · Science · doi:10.1126/science.1202998 · Cited by 1,214
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M. (2001) · Genome Research · doi:10.1101/gr.gr-1649r · Cited by 1,113
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Tamkun, J. W., DeSimone, D. W., Fonda, D., Patel, R. S., Buck, C., Horwitz, A. F., & Hynes, R. O. (1986) · Cell · doi:10.1016/0092-8674(86)90744-0 · Cited by 871
Wang, C., Tao, H., Cheng, L., & Liu, Z. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.007 · Cited by 824
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Toward understanding and exploiting tumor heterogeneity
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746
DNA Origami as a Carrier for Circumvention of Drug Resistance
Jiang, Q., Song, C., Nangreave, J., Liu, X., Lin, L., Qiu, D., Wang, Z.-G., Zou, G., Liang, X., Yan, H., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304263n · Cited by 736
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationPrinciples in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Mechanisms of Drug Resistance in Cancer Chemotherapy
Luqmani, Y. A. (2005) · Medical Principles and Practice · doi:10.1159/000086183 · Cited by 651
DNA Origami as an In Vivo Drug Delivery Vehicle for Cancer Therapy
Zhang, Q., Jiang, Q., Li, N., Dai, L., Liu, Q., Song, L., Wang, J., Li, Y., Tian, J., Ding, B., et al. (2014) · ACS Nano · doi:10.1021/nn502058j · Cited by 643
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
Zhong, Z., Sanchez-Lopez, E., & Karin, M. (2016) · Cell · doi:10.1016/j.cell.2016.05.051 · Cited by 576
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Drug Release from Electric-Field-Responsive Nanoparticles
Ge, J., Neofytou, E., Cahill, T. J., Beygui, R. E., & Zare, R. N. (2012) · ACS Nano · doi:10.1021/nn203430m · Cited by 534
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
Self-citationCellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Inflammatory networks underlying colorectal cancer
Lasry, A., Zinger, A., & Ben-Neriah, Y. (2016) · Nature Immunology · doi:10.1038/ni.3384 · Cited by 489
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationPlatt, V. M., & Szoka, F. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800024g · Cited by 456
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Self-citationABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
The folate receptor as a rational therapeutic target for personalized cancer treatment
Assaraf, Y. G., Leamon, C. P., & Reddy, J. A. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.10.002 · Cited by 398
Self-citationVitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours
Russell-Jones, G., McTavish, K., McEwan, J., Rice, J., & Nowotnik, D. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.07.009 · Cited by 392
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Wei, T., Chen, C., Liu, J., Liu, C., Posocco, P., Liu, X., Cheng, Q., Huo, S., Liang, Z., Fermeglia, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418494112 · Cited by 370
Mechanical Force-Triggered Drug Delivery
Zhang, Y., Yu, J., Bomba, H. N., Zhu, Y., & Gu, Z. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00369 · Cited by 354
The folate receptor: What does it promise in tissue-targeted therapeutics?
Salazar, M. D., & Ratnam, M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9048-0 · Cited by 350
Molecular basis of antifolate resistance
Assaraf, Y. G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9049-z · Cited by 338
Self-citationToward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Tortorella, S., & Karagiannis, T. C. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9637-0 · Cited by 312
Jiang, L., Li, L., He, X., Yi, Q., He, B., Cao, J., Pan, W., & Gu, Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.004 · Cited by 294
Zhong, Y., Zhang, J., Cheng, R., Deng, C., Meng, F., Xie, F., & Zhong, Z. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.012 · Cited by 286
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Clinical Implications of Genomic Discoveries in Lung Cancer
Swanton, C., & Govindan, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1504688 · Cited by 269
Choi, K. Y., Saravanakumar, G., Park, J. H., & Park, K. (2012) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.10.029 · Cited by 264
Building a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy
Wu, C., Han, D., Chen, T., Peng, L., Zhu, G., You, M., Qiu, L., Sefah, K., Zhang, X., & Tan, W. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4094617 · Cited by 260
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Self-citationMultidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Yu, H., Cui, Z., Yu, P., Guo, C., Feng, B., Jiang, T., Wang, S., Yin, Q., Zhong, D., Yang, X., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404484 · Cited by 253
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Senzer, N., Nemunaitis, J., Nemunaitis, D., Bedell, C., Edelman, G., Barve, M., Nunan, R., Pirollo, K. F., Rait, A., & Chang, E. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.32 · Cited by 236
The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
Wu, C.-P., Hsieh, C.-H., & Wu, Y.-S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200261n · Cited by 234
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells
Huang, Y., & Sadée, W. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.032 · Cited by 230
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W., Chung, V., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 230
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
Self-citationGuo, X., Wei, X., Jing, Y., & Zhou, S. (2015) · Advanced Materials · doi:10.1002/adma.201502865 · Cited by 222
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Self-citationNanoparticle Albumin-Bound Paclitaxel: A Novel Cremphor-EL ® -Free Formulation of Paclitaxel
Stinchcombe, T. E. (2007) · Nanomedicine · doi:10.2217/17435889.2.4.415 · Cited by 205
Du, J.-Z., Mao, C.-Q., Yuan, Y.-Y., Yang, X.-Z., & Wang, J. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.002 · Cited by 202
Zheng, C., Zheng, M., Gong, P., Deng, J., Yi, H., Zhang, P., Zhang, Y., Liu, P., Ma, Y., & Cai, L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.053 · Cited by 200
Schmitt‐Sody, M., Strieth, S., Krasnici, S., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., Naujoks, K., & Dellian, M. (2003) · PubMed · Cited by 192
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Self-citationRecognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells
Zhao, Z., Xu, L., Shi, X., Tan, W., Fang, X., & Shangguan, D. (2009) · The Analyst · doi:10.1039/b904476k · Cited by 179
Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds
Sun, T.-M., Wang, Y.-C., Wang, F., Du, J.-Z., Mao, C.-Q., Sun, C.-Y., Tang, R.-Z., Liu, Y., Zhu, J., Zhu, Y.-H., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.011 · Cited by 174
Yin, T., Wang, P., Li, J., Wang, Y., Zheng, B., Zheng, R., Cheng, D., & Shuai, X. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.072 · Cited by 171
Pan, H., Liu, L., & Cai, L. (2022) · Biomaterial Engineering · doi:10.1007/978-981-16-5419-0_18 · Cited by 165
Tumor-Elicited Inflammation and Colorectal Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.014 · Cited by 161
Ko, A. H., Tempero, M. A., Shan, Y.-S., Su, W.-C., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Theranostic barcoded nanoparticles for personalized cancer medicine
Yaari, Z. A., da Silva, D., Zinger, A., Goldman, E., Kajal, A., Tshuva, R., Barak, E., Dahan, N., Hershkovitz, D., Goldfeder, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13325 · Cited by 153
Liao, Z., Chuang, E., Lin, C.-C., Ho, Y., Lin, K., Cheng, P., Chen, K., Wei, H.-J., & Sung, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.032 · Cited by 145
Xu, X., Wang, L., Xu, H.-Q., Huang, X., Qian, Y.-D., & Xiang, J. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2591 · Cited by 144
Bao, Y., Guo, Y., Zhuang, X., Li, D., Cheng, B., Tan, S., & Zhang, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500384d · Cited by 143
Zhan, Y., Gonçalves, M., Yi, P., Capelo, D., Zhang, Y., Rodrigues, J., Liu, C., Tomás, H., Li, Y., & He, P. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00468c · Cited by 142
Awada, A. H., Bondarenko, I., Bonneterre, J. M., Nowara, E., Ferrero, J.-M., Bakshi, A. V., Wilke, C., & Piccart, M. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu025 · Cited by 142
Conde, J., Oliva, N., & Artzi, N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421229112 · Cited by 139
Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles
Yu, P., Yu, H., Guo, C., Cui, Z., Chen, X., Yin, Q., Zhang, P., Yang, X., Cui, H., & Li, Y. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.12.001 · Cited by 137
Chang, P., Peng, S., Lee, C., Lu, C., Tsai, S.-C., Shieh, T., Wu, T.-S., Tu, M., Chen, M. Y., & Yang, J. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2050 · Cited by 137
Yoon, H. Y., Son, S., Lee, S. J., You, D. G., Yhee, J. Y., Park, J. H., Swierczewska, M., Lee, S., Kwon, I. C., Kim, S. H., et al. (2014) · Scientific Reports · doi:10.1038/srep06878 · Cited by 136
Shapira, A., Davidson, I., Avni, N., Assaraf, Y. G., & Livney, Y. D. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.022 · Cited by 135
Self-citationLiposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer
Qu, M., Zeng, R., Fang, S., Dai, Q., Li, H., & Long, J. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.019 · Cited by 134
Zheng, W., Cao, C., Liu, Y., Yu, Q., Zheng, C., Sun, D., Ren, X., & Liu, J. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.08.035 · Cited by 134
Su, Y., Hu, Y., Du, Y., Huang, X., He, J., You, J., Yuan, H., & Hu, F. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500710x · Cited by 120
Ke, C., Chiang, W., Liao, Z.-X., Chen, H., Lai, P., Sun, J., & Sung, H. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.023 · Cited by 119
Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier
Lu, J., Zhao, W., Huang, Y., Liu, H., Marquez, R. T., Gibbs, R. B., Jiang, L., Venkataramanan, R., Xu, L., Li, S., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500389v · Cited by 118
Mei, L., Zhu, G., Qiu, L., Wu, C. S., Chen, H., Liang, H., Cansız, S., Lv, Y., Zhang, X., & Tan, W. (2015) · Nano Research · doi:10.1007/s12274-015-0841-8 · Cited by 118
Camp, E. R., Wang, C., Little, E. C., Watson, P. M., Pirollo, K. F., Rait, A. S., Cole, D. J., Chang, E. H., & Watson, D. K. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.9 · Cited by 115
He, Z., Huang, J., Xu, Y., Zhang, X., Teng, Y., Huang, C., Wu, Y., Zhang, X., Zhang, H., & Sun, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6243 · Cited by 112
Amjad, M. W., Amin, M. C. I. M., Katas, H., Butt, A. M., Kesharwani, P., & Iyer, A. K. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00827 · Cited by 112
Novel Extracellular Vesicles Mediate an ABCG2-Dependent Anticancer Drug Sequestration and Resistance
Ifergan, I., Scheffer, G. L., & Assaraf, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2021 · Cited by 110
Self-citationHe, X., Wang, J., Wei, W., Shi, M., Xin, B., Zhang, T., & Shen, X. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139228 · Cited by 106
Wang, H., Zhao, Y., Wang, H., Gong, J., He, H., Shin, M. C., Yang, V. C.-M., & Huang, Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.051 · Cited by 105
Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance
Goler-Baron, V., & Assaraf, Y. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016007 · Cited by 104
Self-citationYu, B., Ruan, M., Dong, X., Yu, Y., & Cheng, H. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.028 · Cited by 103
Li, Z., Qiu, L., Chen, Q., Hao, T., Qiao, M., Zhao, H., Zhang, J., Hu, H., Zhao, X., Chen, D., et al. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.09.014 · Cited by 103
Kong, F., Wang, W., Xi, M., Duan, X., & Wang, Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80297 · Cited by 100
Zhao, Y. S., Zhou, Y., Wang, D., Gao, Y., Li, J., Ma, S., Zhao, L., Zhang, C., Liu, Y., & Li, X. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.01.010 · Cited by 100
Wu, Y., Zhang, Y., Zhang, W., Sun, C., Wu, J., & Tang, J. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.11.041 · Cited by 100
Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting
Song, S., Qi, H., Xu, J., Guo, P., Chen, F., Li, F., Yang, X., Sheng, N., Wu, Y., & Pan, W. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1393-4 · Cited by 94
Jia, L., Li, Z., Shen, J., Zheng, D., Tian, X., Guo, H., & Chang, P. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.010 · Cited by 93
Franchini, M. C., Baldi, G., Bonacchi, D., Gentili, D., Giudetti, G., Lascialfari, A., Corti, M., Marmorato, P., Ponti, J., Micotti, E., et al. (2009) · Small · doi:10.1002/smll.200901689 · Cited by 93
Actively Targeted Nanoparticles for Drug Delivery to Tumor
Bi, Y., Hao, F., Yan, G., Teng, L., Lee, R. J., & Xie, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666160619191853 · Cited by 93
Slingerland, M., Guchelaar, H., Rosing, H., Scheulen, M. E., van Warmerdam, L. J. C., Beijnen, J. H., & Gelderblom, H. A. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.10.009 · Cited by 89
A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer
Bu, H., He, X., Zhang, Z., Yin, Q., Yu, H., & Li, Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.039 · Cited by 88
Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
Gilad, Y., Firer, M. A., & Gellerman, G. (2016) · Biomedicines · doi:10.3390/biomedicines4020011 · Cited by 87
Goler-Baron, V., Sladkevich, I., & Assaraf, Y. G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.033 · Cited by 83
Self-citationIvey, J. W., Bonakdar, M., Kanitkar, A., Davalos, R. V., & Verbridge, S. S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.019 · Cited by 83
Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer
Wang, H., Li, F., Du, C., Wang, H., Mahato, R. I., & Huang, Y. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400687w · Cited by 83
Bar-Zeev, M., Assaraf, Y. G., & Livney, Y. D. (2016) · Oncotarget · doi:10.18632/oncotarget.8019 · Cited by 81
Self-citationLiang, D., Wang, A.-T., Yang, Z., Liu, Y., & Qi, X. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00129 · Cited by 81
Raz, S., Stark, M., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.004 · Cited by 81
Self-citationAwada, A. H., García, A. A., Chan, S. Y. T., Jérusalem, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70429-7 · Cited by 80
Blau, R., Krivitsky, A., Epshtein, Y., & Satchi‐Fainaro, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.003 · Cited by 79
Deeken, J. F., Slack, R. S., Weiss, G. J., Ramanathan, R. K., Pishvaian, M. J., Hwang, J. J., Lewandowski, K., Subramaniam, D. S., He, A. R., Cotarla, I., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2048-y · Cited by 78
Liu, Y., Mei, L., Yu, Q., Xu, C., Qiu, Y., Yang, Y., Shi, K., Zhang, Q., Gao, H., Zhang, Z., et al. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b04596 · Cited by 78
Dai, X.-Y., Zhuang, L., Wang, D., Zhou, T., Chang, L.-L., Gai, R., Zhu, D., Yang, B., Zhu, H., & He, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.6903 · Cited by 75
Qian, J., Xu, M., Suo, A., Xu, W., Liu, T., Liu, X., Yao, Y., & Wang, H. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.12.018 · Cited by 73
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine
Drinberg, V., Bitcover, R., Rajchenbach, W., & Peer, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.026 · Cited by 72
Overcoming multidrug resistance with nanomedicines
Ganoth, A., Merimi, K. C., & Peer, D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.960920 · Cited by 72
Fan, X., Chai, L., Zhang, H., Wang, Y., Zhang, B., & Gao, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126051 · Cited by 71
Elumalai, R., Patil, S. S., Maliyakkal, N., Rangarajan, A., Kondaiah, P., & Raichur, A. M. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.01.005 · Cited by 70
Guo, S., Lv, L., Shen, Y., Hu, Z., He, Q., & Chen, X. S. (2016) · Scientific Reports · doi:10.1038/srep21459 · Cited by 69
In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier
Wang, Y., Zhao, R., Wang, S., Liu, Z., & Tang, R. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.09.030 · Cited by 68
Chiu, H., Chen, H., Huang, W., Chiang, W., Liu, T., Shen, M., Hsu, Y., & Lin, S. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s86053 · Cited by 66
Sun, M., Yang, C., Zheng, J., Wang, M., Chen, M., Le, D. Q. S., Kjems, J., & Bünger, C. E. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.09.029 · Cited by 65
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
Momparler, R. L. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-20 · Cited by 65
Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
Raz, S., Sheban, D., Gonen, N., Stark, M., Berman, B., & Assaraf, Y. G. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.39 · Cited by 64
Self-citationLiu, L., Chang, S., Sun, J., Zhu, S., Yin, M., Zhu, Y., Wang, Z., & Xu, R. X. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.052 · Cited by 63
Misra, R., Das, M., Sahoo, B. S., & Sahoo, S. K. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.056 · Cited by 62
Sriraman, S. K., Pan, J., Sarısözen, C., Luther, E., & Torchilin, V. P. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00663 · Cited by 61
Abouzeid, A. H., Patel, N. R., Sarısözen, C., & Torchilin, V. P. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1295-x · Cited by 59
Folate receptor-β constitutes a marker for human proinflammatory monocytes
Shen, J., Hilgenbrink, A. R., Xia, W. G., Feng, Y., Dimitrov, D. S., Lockwood, M. B., Amato, R. J., & Low, P. S. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ab0713-372r · Cited by 58
Li, X., Yang, X., Lin, Z., Wang, D., Mei, D., He, B., Wang, X., Wang, X., Zhang, Q., & Gao, W. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.04.018 · Cited by 56
Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy
Nogueira-Librelotto, D. R., Codevilla, C. F., Farooqı, A. A., & Rolim, C. M. B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666161026162347 · Cited by 55
Chen, Q., Yu, Q., Liu, Y., Bhavsar, D., Yang, L., Ren, X., Sun, D., Zheng, W., Liu, J., & Chen, L. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.04.011 · Cited by 54
Qin, M., Lee, Y.-E. K., Ray, A., et al. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201400035 · Cited by 54
Patnaik, A., Papadopoulos, K. P., Tolcher, A. W., Beeram, M., Urien, S., Schaaf, L. J., Tahiri, S., Bekaii‐Saab, T., Lokiec, F. M., Rezaï, K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2149-2 · Cited by 54
Goler-Baron, V., & Assaraf, Y. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035487 · Cited by 54
Self-citationLiang, B., Shahbaz, M., Wang, Y., Gao, H., Fang, R., Niu, Z., Liu, S., Wang, B., Sun, Q., Niu, W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1194 · Cited by 53
Ma, Y., Wang, J., Tao, W., Sun, C., Wang, Y., Li, D., Fan, F., Qian, H., & Yang, X. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b09195 · Cited by 53
Infante, J. R., Keedy, V. L., Jones, S. F., Zamboni, W. C., Chan, E. W., Bendell, J. C., Lee, W., Wu, H., Ikeda, S., Kodaira, H., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1960-5 · Cited by 49
Sawant, R. R., Jhaveri, A. M., Koshkaryev, A., Qureshi, F., & Torchilin, V. P. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.789032 · Cited by 48
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
Qiu, L., Gao, M., & Xu, Y. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s91463 · Cited by 47
Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice
Nguyen, D. H., Lee, J. S., Bae, J. W., Choi, J. H., Lee, Y., Son, J. Y., & Park, K. D. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.083 · Cited by 41
Li, N., Zhang, P., Huang, C., Song, Y., Garg, S., & Luan, Y. (2015) · RSC Advances · doi:10.1039/c5ra15313a · Cited by 41
Wang, Y., Guo, M., Yu, L., Ding, L.-Y., Ron, W.-T., Liu, Y., Song, F.-F., & Yu, S. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/49/495103 · Cited by 41
Chen, B., Guo, L., Zhang, H., Wang, F., Liu, P., Wang, Y., Xia, G., Liu, R., Li, X., yin, H., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s85587 · Cited by 40
Klánová, M., Lorková, L., Vít, O., Maswabi, B. C. L., Molinský, J., Pospíšilová, J., Vočková, P., Mavis, C. K., Latečková, L., Kulvait, V., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-159 · Cited by 40
Tang, B., Fang, G., Gao, Y., Liu, Y., Liu, J., Zou, M., Wang, L., & Cheng, G. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2015.04.004 · Cited by 39
Nanomedicine: a pharma perspective
Brown, P. D. N., & Patel, P. R. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1288 · Cited by 36
Zafar, S., Negi, L. M. S., Verma, A. K., Kumar, V., Tyagi, A., Singh, P., Iqbal, Z., & Talegaonkar, S. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.10.061 · Cited by 35
Jäger, A., Jäger, E., Surman, F., Höcherl, A., Angelov, B., Ulbrich, K., Drechsler, M., Garamus, V. M., Rodriguez‐Emmenegger, C., Nallet, F., et al. (2015) · Polymer Chemistry · doi:10.1039/c5py00567a · Cited by 35
Chen, Y., Zhang, W., Huang, Y., Gao, F., & Fang, X. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s86827 · Cited by 31
Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Urbinati, G., Marsaud, V., & Renoir, J. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612803531423 · Cited by 25
Xu, M., Qian, J., Suo, A., Liu, T., Liu, X., & Wang, H. (2015) · Polymer Chemistry · doi:10.1039/c5py00034c · Cited by 21
Zhang, R., Wang, S., Chen, A., Chen, W., Liu, Y., Wu, W., Kang, Y., & Ye, S.-F. (2015) · Journal of Biomaterials Applications · doi:10.1177/0885328215579297 · Cited by 19
Zhang, H., Fan, X., Li, F., Suo, R., Li, H., Yang, Z. C., Zhang, W., Bai, Y., & Tian, W. J. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb00530b · Cited by 18
ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition
Massey, P. R., Fojo, T., & Bates, S. E. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_20 · Cited by 15
Lin, J., Li, Y., Wu, H., Yang, X., Li, Y., Ye, S., Hou, Z., & Lin, C. (2015) · RSC Advances · doi:10.1039/c4ra14602f · Cited by 12
Cited by
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Self-citationThe multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Self-citationMoradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Wang, X., Zhang, H., Yang, H., Bai, M., Ning, T., Deng, T., Liu, R., Fan, Q., Zhu, K., Li, J., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12629 · Cited by 490
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Metadata
- Authors
- Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 31
- Pages
- 15-30
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2614719195
- Cited by
- 314
- References
- 166
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.